NuCana (NCNA) Total Non-Current Liabilities (2017 - 2025)
NuCana (NCNA) reported Total Non-Current Liabilities of $949738.7 for Q4 2025, up 380.49% on a YoY basis from $197659.3 in Q4 2024, and up 496.48% sequentially from $159224.7 in Q3 2025.
NuCana (NCNA) Total Non-Current Liabilities (2017 - 2025) Analysis & Trends
NuCana (NCNA) has 9 years of Total Non-Current Liabilities data on file, last reported at $949738.7 in Q4 2025.
- For the quarter ending Q4 2025, Total Non-Current Liabilities rose 380.49% year-over-year to $949738.7; the trailing twelve-month figure through Dec 2025 stood at $949738.7 (up 380.49% YoY), and the FY2025 full-year result was $941416.4, up 378.23% from the prior year.
- Total Non-Current Liabilities improved to $949738.7 in Q4 2025, from $159224.7 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $949738.7 in Q4 2025 to a low of $159224.7 in Q3 2025.
- A 5-year average of $352188.9 and a median of $299782.4 in 2023 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities tumbled 48.09% in 2021 and surged 380.49% in 2025, its largest moves.
- Tracing NCNA's Total Non-Current Liabilities over 5 years: stood at $283082.2 in 2021, then surged by 83.14% to $518434.3 in 2022, then sank by 40.63% to $307805.7 in 2023, then tumbled by 35.78% to $197659.3 in 2024, then surged by 380.49% to $949738.7 in 2025.
- Business Quant data shows NCNA's Total Non-Current Liabilities at $949738.7 in Q4 2025, $159224.7 in Q3 2025, and $182764.3 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 4.05 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 949,738.67 |
| Sep 30, 2025 | 159,224.73 |
| Jun 30, 2025 | 182,764.26 |
| Mar 31, 2025 | 171,292.07 |
| Dec 31, 2024 | 197,659.28 |
| Sep 30, 2024 | 213,085.23 |
| Jun 30, 2024 | 267,590.80 |
| Mar 31, 2024 | 291,759.18 |
| Dec 31, 2023 | 307,805.67 |
| Sep 30, 2023 | 354,671.74 |
| Jun 30, 2023 | 421,709.38 |
| Mar 31, 2023 | 481,341.77 |
| Dec 31, 2022 | 518,434.32 |
| Sep 30, 2022 | 595,166.89 |
| Jun 30, 2022 | 206,527.53 |
| Mar 31, 2022 | 250,923.28 |
| Dec 31, 2021 | 283,082.23 |
| Sep 30, 2021 | 332,238.59 |
| Jun 30, 2021 | 387,170.73 |
| Mar 31, 2021 | 471,590.91 |